@reservoir 例えばこの試験ですね。 https://t.co/yfS5rfzdml
RT @LCHeathcote: Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in…
RT @LCHeathcote: Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in…
I need to read this paper. @POCOG1 @jasmineyee_ @UTS_CST
RT @LCHeathcote: Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in…
RT @LCHeathcote: Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in…
RT @LCHeathcote: Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in…
Sobre la eficacia del placebo para reducir la fatiga en supervivientes de un cáncer. 👇
Some interesting new findings from Chris Recklitis & co suggesting efficacy of #openlabelplacebo for reducing #fatigue in #cancer survivors, with efficacy moderated via COMT genetic variation https://t.co/5HmwJGkSpi https://t.co/0VEYyuyLJk
Open-label placebo reduces fatigue in cancer survivors: a randomized trial. https://t.co/hYRmd3snrh
Open-label placebo reduces #fatigue in cancer survivors: a randomized trial. - PubMed - NCBI https://t.co/D96B0OIxu7 #cancer #oncology #research #cancersurvivors #cancerpatients #qualityoflife #health
Open-label placebo reduces fatigue in cancer survivors: a randomized trial. https://t.co/T7GPdNdVhB